If you have been reading about retatrutide and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-03-07. Where a claim depends on a specific study, the study is described rather than over-claimed.
Retatrutide is an investigational synthetic peptide designed to activate three distinct receptor systems within a single molecule. Its pharmacological profile combines activity at the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor. This arrangement places it within a broader class of agents often described as multi-agonists, which contrast with compounds that engage one or two targets. Research interest centers on whether simultaneous signaling produces effects that single-receptor agonists cannot achieve alone. A single molecular entity also simplifies manufacturing and delivery logistics compared with combining separate agents.
Mechanistic proposals link each receptor to a different physiological role. Activation of the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors is associated with reduced appetite, slower gastric emptying, and glucose-dependent insulin release. Glucagon receptor signaling, by contrast, is associated with increased energy expenditure and altered lipid handling, though it can also raise blood glucose. The design intent is to balance these contributions so that weight reduction is enhanced without unacceptable glycemic trade-offs. How well that balance holds across individuals is not fully resolved.
Published information places retatrutide in clinical development rather than on the market as an approved therapy. Early-stage and mid-stage trials have examined tolerability and changes in body weight, and larger studies continue to report results over time. Open questions include the durability of effects after treatment stops, the composition of weight lost, and cardiovascular outcomes over long periods. Statements about definitive benefit should therefore be treated as provisional. Regulatory status varies by jurisdiction and changes as applications are reviewed.
Receptor activation produces downstream effects that differ by tissue. GLP-1 receptor signaling influences appetite regulation and insulin secretion in a glucose-dependent manner. GIP receptor activity contributes to metabolic handling of nutrients and may modulate adipose tissue. Glucagon receptor engagement raises energy expenditure and promotes hepatic lipid turnover, though the balance among these actions in humans is still being characterized. Preclinical models showed reductions in body weight and improved glycemic markers.
Clinical development has progressed through phase 2 trials in adults with obesity and type 2 diabetes, with phase 3 programs reported as ongoing. Reported outcomes include reductions in body weight and improvements in glycemic measures over defined treatment periods. Whether these effects translate into durable benefits after treatment ends remains an open question. Long-term safety data across broad populations are not yet complete, and regulatory decisions have not been announced.
Retatrutide is an investigational synthetic peptide engineered to activate three distinct hormone receptors within a single molecule. It targets the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor simultaneously. This triagonist design distinguishes it from earlier incretin-based compounds that act on one or two of these pathways. Structural modifications relative to native gut hormones extend its residence time in circulation. The molecule remains under clinical evaluation and is not approved for any indication.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Studied for metabolic indications |
| Receptor activity | GIP, GLP-1, and glucagon | Single molecule, three targets |
| Development status | Investigational | Not an approved therapy |
| Common synonym | LY3437943 | Development designation |
| Administration route | Subcutaneous injection | As used in clinical studies |
Development has progressed from single- and multiple-ascending-dose studies in healthy volunteers into larger randomized trials in adults with obesity, type 2 diabetes, and fatty liver disease. Early reports describe dose-dependent reductions in body weight and improvements in glycemic markers over treatment periods of several months. Whether the glucagon arm adds tolerability cost without added benefit is still debated. Long-term cardiovascular outcomes, effects after treatment stops, and performance in older or comorbid populations are open questions rather than settled findings. Approval status may change, so the current investigational label should be confirmed against regulatory sources.
Retatrutide is an investigational synthetic peptide developed under the code LY3437943, with a backbone derived from glucose-dependent insulinotropic polypeptide. Several non-proteinogenic residues, including alpha-aminoisobutyric acid, appear in that backbone, and a fatty diacid side chain attached through a linker extends circulation time. The molecule carries roughly thirty-nine amino acid units and a total mass near 4.7 kilodaltons. Administration is by subcutaneous injection once weekly. Published work uses both the name retatrutide and the code LY3437943.
Pharmacologically the compound activates three receptors: GLP-1, GIP, and glucagon. GLP-1 and GIP signaling contribute to glucose-dependent insulin release, delayed gastric emptying, and reduced appetite, while glucagon receptor activation is associated with increased energy expenditure and hepatic fat oxidation. The single-molecule design is intended to keep these activities in one peptide rather than combining separate agents. Relative activity at each receptor differs, and the balance between them is a central question in interpretation. The glucagon component is partly offset by incretin-mediated insulin secretion, an interaction that remains incompletely characterized.
Human evidence remains limited to controlled studies. A phase 2 trial in adults with obesity reported large, dose-dependent reductions in body weight over 48 weeks, with gastrointestinal events as the most frequently recorded adverse effect. Phase 3 programs designated TRIUMPH, for obesity, and TRANSCEND, for type 2 diabetes, are intended to confirm efficacy and to characterize safety in larger populations. Related studies are examining conditions such as knee osteoarthritis in people with obesity and metabolic liver disease. Open questions include long-term tolerability, effects on lean mass, and what happens after treatment is stopped.
Retatrutide is an investigational synthetic peptide that acts on three receptor targets at once: glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, and glucagon. It is developed by Eli Lilly and appears in the literature and in trial registries under the code LY3437943. The molecule belongs to a class of engineered peptides designed to resist rapid breakdown and permit infrequent subcutaneous administration. No regulatory agency has approved it for clinical use, and all available human data come from controlled trials rather than from routine practice.
==== On Natural Amino Acids ==== Rh-catalyzed Trp and Cys alkylation Using in situ generated RhII-carbenoid by activation of vinyl-substituted diazo compounds with Rh2(OAc)4, tryptophans and cysteines were shown to be selectively alkylated in aqueous media. However, this method is limited to surface tryptophans and cysteines possibly because of steric constraints.
A continuity equation or transport equation is an equation that describes the transport of some quantity. It is particularly simple and powerful when applied to a conserved quantity, but it can be generalized to apply to any extensive quantity. Since mass, energy, momentum, electric charge and other natural quantities are conserved under their respective appropriate conditions, a variety of physical phenomena may be described using continuity equations. Continuity equations are a stronger, local form of conservation laws. For example, a weak version of the law of conservation of energy states that energy can neither be created nor destroyed—i.e., the total amount of energy in the universe is fixed. This statement does not rule out the possibility that a quantity of energy could disappear from one point while simultaneously appearing at another point. A stronger statement is that energy is locally conserved: energy can neither be created nor destroyed, nor can it "teleport" from one place to another—it can only move by a continuous flow. A continuity equation is the mathematical way to express this kind of statement. For example, the continuity equation for electric charge states that the amount of electric charge in any volume of space can only change by the amount of electric current flowing into or out of that volume through its boundaries.
The earliest known members of the reptile lineage appeared during the late Carboniferous period, having evolved from advanced reptiliomorph tetrapods which became increasingly adapted to life on dry land. Genetic and fossil data argues that the two largest lineages of reptiles, Archosauromorpha (crocodilians, birds, and kin) and Lepidosauromorpha (lizards, and kin), diverged during the Permian period. In addition to the living reptiles, there are many diverse groups that are now extinct, in some cases due to mass extinction events. In particular, the Cretaceous–Paleogene extinction event wiped out the pterosaurs, plesiosaurs, and all non-avian dinosaurs alongside many species of crocodyliforms and squamates (e.g., mosasaurs). Modern non-bird reptiles inhabit all the continents except Antarctica. Extant reptiles range in size from the tiny Jaragua dwarf gecko (Sphaerodactylus ariasae), which only grow up to 17 mm (0.7 in); to the saltwater crocodile (Crocodylus porosus), which can reach over 6 m (19.7 ft) in length and weigh over 1,000 kg (2,200 lb). As tetrapods, reptiles generally have four limbs or, in the case of snakes and legless lizards, are descended from four-limbed ancestors but have lost the limbs through evolution. Unlike the anamniotic amphibians, reptiles do not rely on waterbodies for reproduction and have no aquatic larval stage. Most reptiles are oviparous with shelled eggs, although several species of squamates are viviparous, as were some extinct marine reptile clades.
Statistical methods, such as significance tests and confidence intervals, which can be interpreted in terms of the frequency of certain outcomes occurring in hypothetical repeated realisations of the same experimental situation. (ICH E9) Full analysis set
Sources: en.wikipedia.org
Hypnale hypnale is a venomous pit viper species endemic to India and Sri Lanka. Common names include the hump-nosed viper, Merrem's hump-nosed viper hump-nosed pit viper, and Oriental hump-nosed viper. No subspecies are currently recognized.
allosome Also sex chromosome, heterochromosome, or idiochromosome. Any chromosome that differs from an ordinary autosome in size, form, or behavior and which is responsible for determining the sex of an organism. In humans, the X chromosome and the Y chromosome are sex chromosomes.
=== Background and origins === Socialist models and ideas espousing common or public ownership have existed since antiquity. Fenner Brockway identified three early democratic socialist groups during the English Civil War in his book Britain's First Socialists, namely the Levellers, who were pioneers of political democracy and the sovereignty of the people; the Agitators, who were the pioneers of participatory control by the ranks at their workplace, and the Diggers, who were pioneers of communal ownership, cooperation and egalitarianism. The philosophy and tradition of the Diggers and the Levellers was continued in the period described by E. P. Thompson in The Making of the English Working Class by Jacobin groups like the London Corresponding Society and by polemicists such as Thomas Paine. Their concern for both democracy and social justice marked them out as key precursors of democratic socialism. The first self-conscious socialist movements developed in the 1820s and 1830s. Western European social critics, including Robert Owen, Charles Fourier, Pierre-Joseph Proudhon, Louis Blanc, Charles Hall, and Henri de Saint-Simon, were the first modern socialists who criticised the excessive poverty and inequality generated by the Industrial Revolution. The first advocates of socialism favoured social levelling in order to create a meritocratic or technocratic society based on individual talent as opposed to aristocratic privilege. Saint-Simon is regarded as the first individual to coin the term socialism.
Nutrition science (theoretical focus) and dietetics (practical focus) is the study of the relationship of food and drink to health and disease, especially in determining an optimal diet. Medical nutrition therapy is done by dietitians and is prescribed for diabetes, cardiovascular diseases, weight and eating disorders, allergies, malnutrition, and neoplastic diseases. Pathology as a science is the study of disease – the causes, course, progression and resolution thereof. Pharmacology is the study of drugs and their actions. Photobiology is the study of the interactions between non-ionizing radiation and living organisms. Physiology is the study of the normal functioning of the body and the underlying regulatory mechanisms. Radiobiology is the study of the interactions between ionizing radiation and living organisms. Toxicology is the study of hazardous effects of drugs and poisons.
== History == Deramciclane was discovered by EGIS Pharmaceuticals Ltd in Budapest, Hungary. In 2000, EGIS signed over exclusive rights to Orion Pharma to further develop, register, and market deramciclane. Successful pre-clinical, Phase I, and Phase II trials looked promising to the company and its investors even up until the third quarter of 2002. Phase I studies show little to no side effects of deramciclane. Phase II studies show little to no side effects and statistically significant improvement on the Hamilton Anxiety Rating Scale in response to daily 60 mg doses, but not in response to daily 10 or 30 mg doses. Finally, in February, 2003, deramciclane development for use against general anxiety disorder (GAD) was discontinued during Phase III trials due to clinically insignificant results compared to placebo groups.
Sources: en.wikipedia.org
=== Names === Selegiline is the generic name of the drug and its INNTooltip International Nonproprietary Name, BANTooltip British Approved Name, and DCFTooltip Dénomination Commune Française, while selegiline hydrochloride is the USANTooltip United States Adopted Name. The word "selegiline" is pronounced (sə-LEJ-i-leen) or as "seh-LEH-ji-leen". Selegiline is also known as L-deprenyl, L-deprenil, L-deprenalin, L-deprenaline, L-phenylisopropylmethylpropinylamine, and L-E-250. It should not be confused with the racemic form, deprenyl (E-250), or with the dextrorotatory enantiomer, D-deprenyl, which are distinct substances. Major brand names of selegiline include Eldepryl, Jumex, and Movergan (oral tablet and/or capsule), Zelapar (orally disintegrating tablet or ODT), and Emsam (transdermal patch). Selegiline has been marketed under more than 70 brand names worldwide. The brand name "Emsam" was derived from the names of two children, Emily and Samuel, of one of the executives at Somerset Pharmaceuticals, the developer of Emsam.
== History, geography and ethnography == In West Africa, the bark, roots, leaves, flowers, fruits, and seeds are commonly used in traditional medicine to treat a wide diversity of complaints, both internally and externally, sometimes in combination with other medicinal plants. The bark is most important for medicinal uses, followed by the leaves. Medicinal applications include the treatment of parasitic infections, circulatory system disorders, such as arterial hypertension, and disorders of the respiratory system, digestive system and skin. In veterinary medicine, a root decoction is used to treat coccidiosis in poultry. Green pods are crushed and added to rivers to kill fish. The tree locust bean is also known as "arbre à farine, fern leaf, irú, monkey cutlass tree, two ball nitta-tree, nété and néré"). The use of fermented locust beans in West Africa was documented as early as the 14th century, and described by Michel Adanson in his Histoire naturelle du Sénégal, published in 1757. Geographically, Parkia biglobosa can be found in a belt stretching from the Atlantic coast in Senegal to southern Sudan and northern Uganda. The tree currently exists within a wide range of natural communities but is most abundant in anthropic communities – places where cultivation is semi-permanent. Annual production of seeds in northern Nigeria is estimated at around 200,000 t. While the products of the tree are not common in international trade, they form an important part of local and regional trade in West Africa.
=== Etymology === Proprioception is from Latin proprius, meaning "one's own", "individual", and capio, capere, to take or grasp. Thus to grasp one's own position in space, including the position of the limbs in relation to each other and the body as a whole. The word kinesthesia or kinæsthesia (kinesthetic sense) refers to movement sense, but has been used inconsistently to refer either to proprioception alone or to the brain's integration of proprioceptive and vestibular inputs. Kinesthesia is a modern medical term composed of elements from Greek; kinein "to set in motion; to move" (from PIE root *keie- "to set in motion") + aisthesis "perception, feeling" (from PIE root *au- "to perceive").
== Laboratory identification == Penicillium digitatum can be identified in the laboratory using a variety of methods. Typically, strains are grown for one week on three chemically defined media under varying temperature conditions. The media used are Czapek Yeast Extract Agar (at 5, 25 and 37 °C), Malt Extract Agar (at 25 °C), and 25% Glycerol Nitrate Agar (at 25 °C). The resulting colonial morphology on these media (described above in § Growth and morphology) allows for identification of P. digitatum. Closely related species in the genus Pencillium can be resolved through this approach by using Creatine Sucrose Neutral Agar. Molecular methods can also aid with identification. The genomes of many species belonging to the genus Penicillium remain to be sequenced, however, limiting the applicability of such methods. Lastly, P. digitatum can also be distinguished macroscopically by the production of yellow-green to olive conidia, and microscopically by the presence of large philades and conidia.
== References == Dean, Adam, and Jonathan Obert. "Rewarded by Friends and Punished by Enemies: The CIO and the Taft-Hartley Act." Labor 18.3 (2021): 78-113. McCann, Irving G. Why the Taft-Hartley Law? New York: Committee for Constitutional Government, 1950. Millis, Harry A. and Brown, Emily Clark. From the Wagner Act to Taft-Hartley: A Study of National Labor Policy and Labor Relations. Chicago: University of Chicago Press, 1950.
Sources: en.wikipedia.org
It is described as a single molecule that acts at three receptors: the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor. This triple activity distinguishes it from agents that target one or two of these pathways.
It is characterized in the literature as an investigational agent under clinical study. Approval status depends on jurisdiction, and readers should check current regulatory information rather than assume availability.
The combination is intended to pair appetite-related and glucose-related effects with mechanisms that increase energy expenditure. Whether the combined profile offers advantages over simpler agonists is the subject of ongoing research.
It is a synthetic peptide triagonist that engages GIP, GLP-1, and glucagon receptors. Investigational compounds in this class are studied for metabolic conditions rather than for a single organ system.